Outcomes After Conversion From Mechanical to Bioprosthetic Valves for Anticoagulation-Related Complications

This retrospective cohort study from the Mayo Clinic analyzed 62 consecutive adult patients undergoing conversion from a mechanical valve to a bioprosthetic valve due to severe anticoagulation-related complications, including major bleeding and systemic thromboembolism. The authors sought to delineate whether this reoperative strategy successfully eliminates the long-term burden of chronic anticoagulation and its associated morbidities. Outcomes revealed a substantial early procedural hazard, with an overall in-hospital mortality rate of 13 percent, predominantly driven by urgent or emergent presentations (58 percent of cases). The authors discuss that prosthesis replacement does not eradicate risk of systemic thrombosis, and 66 percent of patients still required continued, long-term Warfarin therapy for concurrent comorbidities such as atrial fibrillation. Accounting for the competing risk of death, the five-year cumulative incidence of recurrent bleeding or thromboembolism was 27 percent, with nearly two-thirds of these subsequent events occurring while patients were therapeutically anticoagulated.